Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Gains from Investment Securities (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Gains from Investment Securities for 3 consecutive years, with -$701000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities fell 229.11% to -$701000.0 in Q4 2025 year-over-year; TTM through Sep 2025 was $488000.0, a 54.6% decrease, with the full-year FY2024 number at $57.7 million, up 88.36% from a year prior.
  • Gains from Investment Securities was -$701000.0 for Q4 2025 at Nuvation Bio, down from $404000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $3.7 million in Q1 2025 to a low of -$3.4 million in Q2 2025.
  • A 3-year average of $131727.3 and a median of $213000.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: surged 12258.33% in 2024, then tumbled 229.11% in 2025.
  • Nuvation Bio's Gains from Investment Securities stood at -$597000.0 in 2023, then surged by 64.32% to -$213000.0 in 2024, then crashed by 229.11% to -$701000.0 in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Gains from Investment Securities are -$701000.0 (Q4 2025), $404000.0 (Q3 2025), and -$3.4 million (Q2 2025).